Score Breakdown
Below average.
Recursion is a clinical-stage TechBio company burning ~$350-400M annually with only ~$75M in lumpy milestone-driven revenue. Despite an impressive AI platform narrative and partnerships with Sanofi/Roche, the company has no approved products, no late-stage pipeline, and deeply negative unit economics. The 43% polyp reduction for REC-4881 in FAP, while encouraging, is not clearly differentiated from cheap generics. With 47.5% short interest, 57% annual dilution, aggressive insider selling, major institutional exits (Mubadala, RA Capital), and a stock down 37% in 6 months, the risk/reward is unfavorable. The $754M cash position provides runway to early 2028, but another massive dilutive raise is inevitable. SBC at 117% of revenue is extraordinary even for biotech. The company needs multiple clinical wins to justify its $1.5B market cap, and each quarter without proof increases the probability of a terminal dilution spiral.
Negative cash flow. Can't value it.
Major red flags in SEC filings.
Shares melting fast.
Execs buying. Skin in the game.
Tight but ok.
Heavy bearish bets.
Below average.
🐻 Why Bears Hate It
The core bear thesis rests on the 'unproven' nature of its AI platform. Critically, lead candidate REC-4881 for FAP showed a median polyp reduction of 43%, which bears argue fails to meaningfully differentiate from 'dirt-cheap' generic alternatives like Celebrex (30% mean reduction), undermining the justification for orphan-drug pricing (Seeking Alpha, Dec 2025). Furthermore, BofA lowered its price target to $6 in March 2026, stating Recursion has yet to prove its OS can reliably generate differentiated patient outcomes beyond early-stage data (Finviz/BofA, March 2026).
🔍 What's In The SEC Filings
Recursion is a capital-intensive entity facing a $2.0 billion accumulated deficit and an unsustainable burn rate that forces constant, massive shareholder dilution to maintain operations.
Extreme and rapid utilization of 'At-The-Market' (ATM) equity offerings to fund operations.
“For the nine months ended September 30, 2025, the Company sold 74.6 million shares and received net proceeds of $358.2 million under the agreement... The remaining amount was fully utilized during October 2025.”
The company exhausted a $500 million shelf in less than a year, indicating a 'burn-to-survive' model that aggressively devalues existing equity holders.
Coordinated adoption of Rule 10b5-1 trading plans by key board members and C-suite executives during a period of heavy restructuring.
“On August 31, 2025, Blake Borgeson, a member of our Board of Directors, adopted a Rule 10b5-1 trading arrangement... for the potential sale of up to 3,868,000 shares.”
The Board and management (including the CFO and Chief R&D Officer) are signaling an exit from their positions shortly after a 20% workforce reduction and while the stock is being used as a currency for acquisitions.
Use of highly subjective 'cost-to-cost' input methods for recognizing revenue on complex AI collaboration agreements.
“The Company recognizes revenue over time based on costs incurred relative to total expected costs... A significant change in these estimates could have a material effect on the timing and amount of revenue recognized.”
Management can accelerate revenue recognition by adjusting internal estimates of total project costs, which is difficult for auditors to verify in a novel 'TechBio' context.
Ongoing litigation involving both securities law violations and a significant commercial lease dispute.
“On June 23, 2023, the landlord filed a lawsuit... alleging anticipatory repudiation, breach of contract... and seeks monetary damages and attorney's fees.”
The company faces multiple legal fronts, including a dismissed-but-refilable securities class action and a breach of contract suit that could result in un-accrued cash outflows.
Intrinsic value is obscured by the $2 billion deficit and constant share issuance; investors should apply a heavy 'dilution discount' and monitor 10b5-1 execution prices as a ceiling for stock performance.
The CEO's Class B shares provide 10:1 voting power, ensuring complete control over mergers or sales regardless of Class A shareholder interests. Furthermore, the 20% workforce reduction in June 2025 suggests the Exscientia integration is more about cost-cutting than synergistic growth.